Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 11 results found. Search for [ Kyowa Pharmaceuticals ]

Results 1 to 11 of 11
PB Jayakumar
January 14, 2020
A couple of days ago, Lupin said that it had received two observations from the US health regulator following the inspection at its Nagpur manufacturing facility, one of its most modern plants


Niti Kiran
December 19, 2019
With 94 deals, the month recorded 38 per cent higher deals compared to November 2018 and 6 per cent higher compared to October 2019


Niti Kiran
November 14, 2019
An improvement in exports to the US, the key market for Indian drug manufacturers, drove the growth in overall exports from India


BusinessToday.In
November 13, 2019
Lupin Pharma has sold the entire stake (99.82%) in its Japanese subsidiary Kyowa to Unison's entity Plutus Ltd, Japan, for an enterprise value of $300 million, subject to closing adjustments


PB Jayakumar
New Delhi, November 12, 2019
The divestment will curtail 13 per cent global revenues of Lupin, which had posted Rs 16,369 crore consolidated revenues for the financial year ended March 31, 2019


PB Jayakumar
New Delhi, November 7, 2019
Lupin's net sales for the quarter stood at Rs 4,296 crore, an increase of 10.4 per cent compared to Rs 3,890 crore in the Q2FY19. The company posted a net loss of Rs 127 crore (after exceptional items) in Q2FY20, compared to Rs 266 crore net profit during the same quarter of the previous year


PB Jayakumar
New Delhi, November 26, 2018
Market changes and increased regulatory oversight in the US have hurt Lupin, but India's third-biggest drug maker is making efforts to come back.


Vinita Gupta
Delhi, September 26, 2016
I have always been inherently passionate and ambitious about work and family, and perhaps it has a lot to do with my genes. Growing up, it was often hard to separate the family from the business of Lupin.


PB Jayakumar
December 25, 2015
Developed markets together now contribute 48% to Lupin's revenue (the bulk, no doubt, coming from the US) and emerging markets another 19%, while the domestic market's share has shrunk to 26 per cent from 31 per cent five years ago.


Suprotip Ghosh
December 23, 2013
Kamal K. Sharma came into Lupin after the company went through tough times. For one, the pharma firm was saddled with a massive Rs 500-crore debt. For another, it had missed the bus on global expansion while its peers such as Ranbaxy had started operations in the US.


Suman Layak
May 26, 2010
For most of its 40 years, Lupin seemed to be just another Indian pharma company trying to make hay in the US generics market. Today, it is a global generics firm to reckon with, taking on giant Teva on the value-creation front.


PAGES 1 OF 1